NCT05229237View on ClinicalTrials.gov

Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

June 5, 2021

Study Completion Date

December 5, 2021

Conditions
Polypoidal Choroidal VasculopathyConbercept
Interventions
DRUG

Conbercept

Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.)

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT05229237 - Conbercept for Polypoidal Choroidal Vasculopathy（START Study） | Biotech Hunter | Biotech Hunter